This report investigates the impacts and development of Genome Editing therapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Scope
This 48-page report gives important, expert insight you won’t find in any other source. 19 figures throughout the report illustrate major points and trends within the Genome Editing market delving deep into forecasted sales and company pipelines. This report is required reading for:- Investors that want to understand past trends impacting the Genome Editing landscape as well as identifying companies to invest in
- Companies that are interested in entering the Genome Editing landscape and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies lead the Genome Editing landscape in the past and how they led
- Small and medium pharma who want to focus their Genome Editing drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on the different types of Genome Editing with current and novel forms
- Insights on past trends and changes that have informed the Genome Editing market
- Insights on the current leading Genome Editing drugs based on their Sales and Forecasts and other parameters
- Therapeutic and Indication insights into the Genome Editing market
- Insights into the future opportunities for Genome Editing and the companies leading in the market.
Table of Contents
1 Introduction to Genome Editing1.1 Description of the different genome editing subtypes
1.2 Spotlight: Casgevy
2 Genome Editors: Previous Years in Review
2.1 Patent trends
2.2 Review designation trends
2.3 Deals value and volume review
3 Genome Editors: Current Landscape
3.1 Genome editor trends by subtype, development stage, indications
3.2 Most active companies in genome editing development
3.3 Top deals by type
3.4 Top clinical trial sponsors
4 Genome Editors: Current Landscape
4.1 Top companies by genome editing forecast sales
4.2 Top genome editors by forecast sales
4.3 Total genome editing market forecast sales
4.4 Upcoming genome editing launches
4.5 Genome editors by highest likelihood of approval (LoA)
5 Key Findings
6 Appendix
6.1 Abbreviations
6.2 Methodology
6.3 About the Authors
6.4 About the Analyst
6.5 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- CRISPR Therapeutics
- Intellia Therapeutics
- YolTech Therapeutics
- Cellectis
- Sangamo Therapeutics
- Modalis Therapeutics
- Metagenomi
- Prime Medicine
- Vertex Pharmaceuticals
- Huldagene Therapeutics
- Beam Therapeutics
- Shanghai BDgene Therapeutics
- General Hospital of the People's Liberation Army
- Regeneron Pharmaceuticals
- KSQ Therapeutics
- CorrectSequence Therapeutics Co Ltd
- Caribou Biosciences Inc
- Genentech Inc
- Allogene therapeutics Inc
- Renji Hospital
- Vor Biopharma
- MeiraFTx Holdings Plc
- City of Hope
